RRM Academy Synopsis
Three PCOS ovulation drugs show different side effect report signals
Letrozole, tamoxifen, and clomiphene each showed different side effect report patterns in PCOS, a 2026 study of US drug safety reports. All 21,730 reports named polycystic ovary syndrome (PCOS, also called PMOS) as the reason for use. About 8 out of 10 involved letrozole.
Key Findings
- The analysis covered 21,730 PCOS-related reports: letrozole 17,185, tamoxifen 4465, and clomiphene 80.
- Letrozole reports rose steadily and peaked at 2323 cases in 2021.
- Tamoxifen and letrozole shared three signals: malignant neoplasm progression, fatigue, and arthralgia.
- Neoplasm categories were the most reported class for tamoxifen (1513 cases) and letrozole (7502 cases). Neutropenia was the top letrozole event (2245 cases).
- Clomiphene reports leaned toward psychiatric disorders (63 cases) and gastrointestinal disorders (55 cases).
Interpretation
This study searched a US drug safety database for signals linked to letrozole, tamoxifen, and clomiphene use in PCOS. Doctors and patients send these reports in on their own. Letrozole and tamoxifen shared signals for tumor growth, tiredness, and joint pain. Clomiphene reports leaned toward mental health and stomach problems. The authors note that letrozole and tamoxifen also treat breast cancer, and past cancer treatment may play a role in the tumor growth signal. The findings support larger studies of side effects from these three drugs.
RRM Context
Restorative reproductive medicine asks why ovulation stops before any drug is picked. The condition is PMOS, formerly called PCOS. PMOS stands for polyendocrine metabolic ovarian syndrome. The authors list PCOS traits: missing ovulation, low progesterone, high androgens, and insulin resistance.
Abstract
Background
Tamoxifen, clomiphene, and letrozole are primary pharmacological options for inducing ovulation in polycystic ovary syndrome (PCOS). Given the high clinical prevalence of PCOS, a comprehensive characterization of the adverse drug event (ADE) profiles associated with these treatments is essential.
Methods
We performed disproportionality analyses using FAERS data to detect ADE signals at the Preferred Term (PT) and System Organ Class (SOC) levels via four established algorithms (ROR, PRR, BCPNN, and EBGM). A drug-ADE network was constructed to visualize these associations.
Results
Of 21,730 identified PCOS-related reports, letrozole predominated (n=17,185), followed by tamoxifen (n=4465) and clomiphene (n=80). Most cases involved women aged 18-65 years (weight: 50-100 kg), primarily from the United States. Letrozole-related reports increased steadily, peaking at 2323 cases in 2021, while tamoxifen and clomiphene counts remained comparatively low. At the PT level, fatigue was a common signal for both tamoxifen and letrozole. Notably, malignant tumor progression, fatigue, and arthralgia emerged as shared signals across all three agents. At the SOC level, ADEs for tamoxifen and letrozole were frequently categorized under neoplasms; letrozole was specifically linked to hematological disorders (e.g, neutropenia). In contrast, clomiphene exhibited stronger associations with psychiatric and gastrointestinal events.
Conclusion
Distinct safety signals characterize these three primary PCOS treatments. These pharmacological variations underscore the necessity of personalized medicine; treatment selection must be tailored to the patient's specific risk profile, with targeted clinical monitoring for relevant ADEs to optimize therapeutic outcomes.
Topics
Keywords
adverse events, clomiphene, food and drug administration adverse event reporting system, letrozole, polycystic ovary syndrome, tamoxifen
